Clinical Trials in Nashville

Showing 15061-15080 of 20,298 trials

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

NCT01409993

The purpose of this study is to determine the effect of chronic PDE5 inhibitor therapy on glucose metabolism in persons with prediabetes.

Impaired Glucose Tolerance

Vanderbilt University78 participantsStarted Aug 2011

Nashville, Tennessee, United States

COMPLETEDPhase 1< 1 mile

Characteristics of Glargine in Type 2 Diabetics

NCT00574912

The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes will show differing effects on endogenous glucose production, glucose disposal and carbohydrate and lipid flux.

Type 2 Diabetes

Vanderbilt University Medical Center20 participantsStarted Mar 2007

Nashville, Tennessee, United States

TERMINATEDNA< 1 mile

FDG-PET in Advanced Melanoma

NCT02236546

This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, \[18F\]fluorodeoxyglucose (FDG), which selectively accumulates in tumors. FDG-PET/CT of advanced melanoma before, during, and after treatment may improve methods for predicting which patients may benefit from therapy.

Recurrent MelanomaStage IIIA MelanomaStage IIIB Melanoma+2 more

Vanderbilt-Ingram Cancer Center3 participantsStarted May 2012

Nashville, Tennessee, United States

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

Characteristics of Glargine in Type 2 Diabetics

FDG-PET in Advanced Melanoma

Find Trials by Condition in Nashville

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Impact Evaluation of the Reducing the Risk Program

EXTEND (Eltrombopag Extended Dosing Study)

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects

Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

Salivary Diagnostic Testing for IVF

BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer